About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Prostate Cancer Clinical Trials in Tennessee | 386 Studies

Clinical Trials Prostate CancerTennessee

Prostate Cancer Clinical Trials in Tennessee

Find 386 clinical trials for prostate cancer near Tennessee. Connect with research centers in your area.

All Prostate Cancer trials nationwide All trials in Tennessee

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 261-280 of 386 trials

TerminatedIsatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced MalignanciesPrimary Objectives: * To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer…NCT03367819·Birmingham, Alabama and 15 others UnknownR-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of RecurrenceRATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.NCT00045123·Homewood, Alabama and 57 others

Prostate Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedOpen- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate CancerThe ProVent study is a randomized, open-label study designed to assess the efficacy of sipuleucel-T in reducing the progression of lower risk non-metastatic prostate cancer…NCT03686683·Gilbert, Arizona and 55 others

Active not recruiting64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerThe aim for this study is to investigate the ability of 64Cu-SAR-bisPSMA PET/CT to detect recurrence of prostate cancerNCT06970847·Irvine, California and 21 others

Active not recruitingCognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate CancerThis clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide.NCT03016741·Los Angeles, California and 4 others

CompletedSafety Study of TAK-700 in Subjects With Prostate Cancer.The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.NCT00569153·Beverly Hills, California and 18 others

CompletedA Study of JNJ-80038114 in Participants With Advanced Stage Prostate CancerThe purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-80038114 in Part 1 (dose escalation) and to determine the safety at the RP2D(s) in Part 2…NCT05441501·Minneapolis, Minnesota and 5 others

Active not recruitingProton Therapy vs. IMRT for Low or Intermediate Risk Prostate CancerWe are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT.NCT01617161·Jacksonville, Florida and 12 others

RecruitingStudy of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid TumorsThis Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx)…NCT06545942·Goodyear, Arizona and 17 others

RecruitingA First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced…NCT07488923·St Louis, Missouri and 6 others

RecruitingStudy of Oral MRT-2359 With Apalutamide in Prostate CancerThis Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer.NCT07745361·Los Angeles, California and 13 others

CompletedHormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerRATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.NCT00005044·Birmingham, Alabama and 260 others

TerminatedMitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic…NCT00452387·La Verne, California and 9 others

Active not recruitingMultiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate CancerThis phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate…NCT03697148·Phoenix, Arizona and 43 others

TerminatedStudy of HPN424 in Patients With Advanced Prostate CancerAn open-label, Phase 1/2a, study of HPN424 as monotherapy to assess the safety, tolerability and PK in patients with advanced prostate cancer refractory to androgen therapyNCT03577028·Los Angeles, California and 14 others

RecruitingPhase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsThis is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of…NCT06784193·Gilbert, Arizona and 24 others

RecruitingA Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate CancerThe purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer.NCT07567846·Scottsdale, Arizona and 5 others

CompletedRadiation Therapy in Treating Patients With Stage II or Stage III Prostate CancerRATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.NCT00002602·Birmingham, Alabama and 227 others

CompletedA Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate CancerThe purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to…NCT03085095·Tucson, Arizona and 161 others

CompletedSafety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPCThis is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory…NCT00286793·Hot Springs, Arkansas and 12 others

PreviousPage 14 of 20Next

Other Conditions in Tennessee

Breast Cancer Lung Cancer Colorectal Cancer Melanoma Leukemia Lymphoma